VIDEO: RevOpsis prepares for first-in-human trials of RO-104

ByRamanath Bhandari, MD

ByAnthony DeFino

ByDavid W. Mullin

Fact checked byChristine Klimanskis, ELS

PARK CITY, Utah — In this Healio Video Perspective from Clinical Trials at the Summit, Ramanath Bhandari, MD, FASRS, of RevOpsis Therapeutics discusses the development of RO-104 for the treatment of retinal disease.

RO-104, the company’s lead candidate molecule, is a trispecific biologic designed to address VEGF-A, VEGF-C and Ang-2. As Healio previously reported, RevOpsis raised $16.5 million in a first seed funding round to advance clinical development of RO-104.

“With these backers, we feel confident going into first-in-human trials in the second half of next year,” Bhandari said.

Published by:

Sources/Disclosures

Collapse

Source:

Bhandari R. RO-104: A novel trispecific monotherapy for retinal diseases. Presented at: Clinical Trials at the Summit; June 8, 2024; Park City, Utah.

Disclosures: Bhandari reports being the co-founder and interim CEO of RevOpsis Therapeutics.

Clinical Trials at the Summit meeting

Read more

VIDEO: RevOpsis prepares for first-in-human trials of RO-104

Related Content